CAS: 116-44-9; 4-Amino-N-(Pyrazin-2-yl)Benzenesulfonamide

相似化合物

6298-35-7 71720-40-6 14423-79-1

上下游产品

4-Nitrobenzenesulfonamide-N-Pyrazinyl
N-(4-(N-(Pyrazin-2-yl)Sulfamoyl)Phenyl)Acetamide 5433-91-0

📜对乙酰胺基苯磺酰胺置于copper(L) Iodide,氯化亚砜,Potassium Carbonate,N,N'-二甲基-1,2-环己二胺体系中,用 甲醇,N,N-二甲基甲酰胺 用作溶剂,化学反应 32.0H,反应生成磺胺吡嗪
参考文献: 3-Phosphoglycerate Dehydrogenase Inhibitors And Uses Thereof[fr] Inhibiteurs De La 3-Phosphoglycérate Déshydrogénase Et Leurs Utilisations
标题: 3-Phosphoglycerate Dehydrogenase Inhibitors And Uses Thereof[fr] Inhibiteurs De La 3-Phosphoglycérate Déshydrogénase Et Leurs Utilisations
摘要:本发明提供了化合物,其组合物以及使用这些化合物的方法.

专利信息

专利号:US-2003180254-A1
优先权日:1995-05-26
标题:Immunologic enhancement with intermittent interleukin-2 therapy
发明人：LANE H CLIFFORD; KOVACS JOSEPH A; FAUCI ANTHONY S
权利人:GOVT OF THE USA AS REPRESENTED
摘要:A method for activating a mammalian immune system entails a series of IL-2 administrations that are effected intermittently over an extended period. Each administration of IL-2 is sufficient to allow spontaneous DNA synthesis in peripheral blood or lymph node cells of the patient to increase and peak, and each subsequent administration follows the preceding administration in the series by a period of time that is sufficient to allow IL-2 receptor expression in peripheral or lymph node blood of the patient to increase, peak and then decrease to 50% of peak value. This intermittent IL-2 therapy can be combined with another therapy which targets a specific disease state, such as an anti-retroviral therapy comprising, for example, the administration of AZT, ddI or interferon alpha. In addition, IL-2 administration can be employed to facilitate in situ transduction of T cells in the context of gene therapy. By this approach the cells are first activated in vivo via the aforementioned IL-2 therapy, and transduction then is effected by delivering a genetically engineered retroviral vector directly to the patient.

专利号:US-5696079-A
优先权日:1993-05-19
标 题:Immunologic enhancement with intermittent interleukin-2 therapy
发明人：LANE H CLIFFORD; KOVACS JOSEPH A; FAUCI ANTHONY S
权利人:US HEALTH
摘要:A method for activating a mammalian immune system entails a series of IL-2 administrations that are effected intermittently over an extended period. Each administration of IL-2 is sufficient to allow spontaneous DNA synthesis in peripheral blood or lymph node cells of the patient to increase and peak, and each subsequent administration follows the preceding administration in the series by a period of time that is sufficient to allow IL-2 receptor expression in peripheral or lymph node blood of the patient to increase, peak and then decrease to 50% of peak value. This intermittent IL-2 therapy can be combined with another therapy which targets a specific disease state, such as an anti-retroviral therapy comprising, for example, the administration of AZT, ddI or interferon alpha. In addition, IL-2 administration can be employed to facilitate in situ transduction of T cells in the context of gene therapy. By this approach the cells are first activated in vivo via the aforementioned IL-2 therapy, and transduction then is effected by delivering a genetically engineered retrovital vector directly to the patient.

专利号:US-6548055-B1
优先权日:1993-05-19
标题:Immunologic enhancement with intermittent interleukin-2 therapy
发明人：LANE H CLIFFORD; KOVACS JOSEPH A; FAUCI ANTHONY S
权利人:US HEALTH
摘要:A method for activating a mammalian immune system entails a series of IL-2 administrations that are effected intermittently over an extended period. Each administration of IL-2 is sufficient to allow spontaneous DNA synthesis in peripheral blood or lymph node cells of the patient to increase and peak, and each subsequent administration follows the preceding administration in the series by a period of time that is sufficient to allow IL-2 receptor expression in peripheral or lymph node blood of the patient to increase, peak and then decrease to 50% of peak value. This intermittent IL-2 therapy can be combined with another therapy which targets a specific disease state, such as an anti-retroviral therapy comprising, for example, the administration of AZT, ddI or interferon alpha. In addition, IL-2 administration can be employed to facilitate in situ transduction of T cells in the context of gene therapy. By this approach the cells are first activated in vivo via the aforementioned IL-2 therapy, and transduction then is effected by delivering a genetically engineered retroviral vector directly to the patient.

专利号:US-2023398101-A1
优先权日:2022-06-09
标题 :Co-agents as Therapy Against Anaerobic Pathogens
发明人：PACE JOHN LEE; HARTSELL THERESA LYNN
权利人:FLEURIR ABX LLC
摘要:Co-agent combinations and/or formulations herein unexpectedly display significantly better antimicrobial activity (e.g., more efficacy and/or more potency) against anaerobic pathogens not previously considered targets. With three or more co-agents, selected from a group of a fosfomycin, a diaminopyridine, a sulfonamide, a beta lactam antibacterial, a bacterial beta-lactamase inhibitor, a bacterial fosfomycin-modifying enzyme, and a bacterial peptidoglycan synthesis inhibitor, the therapeutic potential of the three or more co-agents is expanded by targeting a broader spectrum of pathogens. Co-agents, by unexpected synergistic action in an anaerobic environment, are now active and efficacious against difficult to treat pathogenic anaerobes (including anaerobes that cannot utilize oxygen and/or reside in an anaerobic environment, some being inhibited by oxygen), as well as pathogens considered resistant or intolerant to at least one of the co-agents when used singly in an anaerobic environment. Some co-agent combinations and/or formulations contain one or more existing antibiotic agents being repurposed for utility against difficult to treat anaerobic pathogens.